Gujarat Magazine

Multiple Sclerosis Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Novartis AG, Sanofi, F. Hoffmann-La Roche, Celgene Crp., Johnson & Johnson

 Breaking News
  • No posts were found

Multiple Sclerosis Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Novartis AG, Sanofi, F. Hoffmann-La Roche, Celgene Crp., Johnson & Johnson

May 22
10:11 2024
Multiple Sclerosis Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Novartis AG, Sanofi, F. Hoffmann-La Roche, Celgene Crp., Johnson & Johnson
In 2023, the Multiple Sclerosis Market size was USD 20.559 billion in the United States and the report offers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the 7MM.

DelveInsight’s “Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Multiple Sclerosis, historical and forecasted epidemiology as well as the Multiple Sclerosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Multiple Sclerosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Multiple Sclerosis Market Forecast

 

Some of the key facts of the Multiple Sclerosis Market Report: 

  • The Multiple Sclerosis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In 2023, the multiple sclerosis market size in the US was about USD 20.559 billion, with expectations for significant growth at a notable CAGR through the study period of 2020 to 2034.

  • Emerging treatments like CNM-Au8 and others have the potential to significantly enhance the Multiple Sclerosis market size.

  • The market size of EU4 and the UK stood at roughly USD 4,555 million and is projected to witness growth throughout the forecast period.

  • In 2023, the total number of prevalent multiple sclerosis cases in the US was recorded at 728,000. These figures are anticipated to undergo significant changes by the year 2034.

  • In 2023, the prevalence of multiple sclerosis cases in Germany, when categorized by gender, showed approximately 61,000 cases among males and 150,000 cases among females.

  • Key Multiple Sclerosis Companies: Clene Nanomedicine, ImStem Biotechnology, Hoffmann-La Roche, Novartis, Johns Hopkins University, NIAID, Eli Lilly and Company, Immunic AG, Celgene, Sanofi, Biogen, Hoffmann-La Roche, Clene Nanomedicine, Kyverna Therapeutics, Mapi Pharma Ltd., Washington University School of Medicine, Bristol-Myers Squibb, and others

  • Key Multiple Sclerosis Therapies: CNM-Au8, IMS001, Fenebrutinib (GDC-0853, RG7845), Fingolimod, Solriamfetol, Ocrelizumab, LY3541860, IMU-838, RPC-1063, Frexalimab, Dimethyl fumarate, Ocrelizumab, gold nanocrystals, KYV-101, GA Depot 80 mg, Cladribine, BMS-986374, and others

  • The Multiple Sclerosis epidemiology based on gender analyzed that in the United States, the prevalence of Multiple Sclerosis is higher in females as compared to males

  • The Multiple Sclerosis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Multiple Sclerosis pipeline products will significantly revolutionize the Multiple Sclerosis market dynamics.

  • The Multiple Sclerosis treatment market looks promising as the market is emerging with newer acute treatments that have been designated by the FDA to treat Multiple Sclerosis. However, large multicenter trials are still necessary to examine the overarching patterns of Multiple Sclerosis and treatment response as a whole.

 

Multiple Sclerosis Overview

Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system (CNS), which includes the brain and spinal cord. In MS, the immune system mistakenly attacks the protective covering of nerve fibers called myelin, causing inflammation and damage to the myelin sheath. 

 

Get a Free sample for the Multiple Sclerosis Market Report: 

https://www.delveinsight.com/report-store/multiple-sclerosis-market

 

Multiple Sclerosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Multiple Sclerosis Epidemiology Segmentation:

The Multiple Sclerosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Multiple Sclerosis

  • Prevalent Cases of Multiple Sclerosis by severity

  • Gender-specific Prevalence of Multiple Sclerosis

  • Diagnosed Cases of Episodic and Chronic Multiple Sclerosis

 

Download the report to understand which factors are driving Multiple Sclerosis epidemiology trends @ Multiple Sclerosis Epidemiology Forecast

 

Multiple Sclerosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Multiple Sclerosis market or expected to get launched during the study period. The analysis covers Multiple Sclerosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Multiple Sclerosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Multiple Sclerosis Therapies and Key Companies

  • CNM-Au8: Clene Nanomedicine

  • IMS001: ImStem Biotechnology

  • Fenebrutinib (GDC-0853, RG7845): Hoffmann-La Roche

  • Fingolimod: Novartis 

  • Solriamfetol: Johns Hopkins University

  • Ocrelizumab: NIAID

  • LY3541860: Eli Lilly and Company

  • IMU-838: Immunic AG

  • RPC-1063: Celgene

  • Frexalimab: Sanofi

  • Dimethyl fumarate: Biogen

  • Ocrelizumab: Hoffmann-La Roche

  • gold nanocrystals: Clene Nanomedicine

  • KYV-101: Kyverna Therapeutics

  • GA Depot 80 mg: Mapi Pharma Ltd.

  • Cladribine: Washington University School of Medicine

  • BMS-986374: Bristol-Myers Squibb

 

Discover more about therapies set to grab major Multiple Sclerosis market share @ Multiple Sclerosis Treatment Market

 

Multiple Sclerosis Market Drivers

  • Increasing population with Multiple Sclerosis

  • Extensive approved therapies

  • Wide range of R&D pipeline

  • Increasing awareness

 

Multiple Sclerosis Market Barriers

  • High cost of drugs

  • High incidence of adverse events

  • Patent expiration

 

Scope of the Multiple Sclerosis Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Multiple Sclerosis Companies: Clene Nanomedicine, ImStem Biotechnology, Hoffmann-La Roche, Novartis, Johns Hopkins University, NIAID, Eli Lilly and Company, Immunic AG, Celgene, Sanofi, Biogen, Hoffmann-La Roche, Clene Nanomedicine, Kyverna Therapeutics, Mapi Pharma Ltd., Washington University School of Medicine, Bristol-Myers Squibb, and others

  • Key Multiple Sclerosis Therapies: CNM-Au8, IMS001, Fenebrutinib (GDC-0853, RG7845), Fingolimod, Solriamfetol, Ocrelizumab, LY3541860, IMU-838, RPC-1063, Frexalimab, Dimethyl fumarate, Ocrelizumab, gold nanocrystals, KYV-101, GA Depot 80 mg, Cladribine, BMS-986374, and others

  • Multiple Sclerosis Therapeutic Assessment: Multiple Sclerosis current marketed and Multiple Sclerosis emerging therapies

  • Multiple Sclerosis Market Dynamics: Multiple Sclerosis market drivers and Multiple Sclerosis market barriers 

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Multiple Sclerosis Unmet Needs, KOL’s views, Analyst’s views, Multiple Sclerosis Market Access and Reimbursement 

 

To know more about Multiple Sclerosis companies working in the treatment market, visit @ Multiple Sclerosis Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Multiple Sclerosis Market Report Introduction

2. Executive Summary for Multiple Sclerosis

3. SWOT analysis of Multiple Sclerosis

4. Multiple Sclerosis Patient Share (%) Overview at a Glance

5. Multiple Sclerosis Market Overview at a Glance

6. Multiple Sclerosis Disease Background and Overview

7. Multiple Sclerosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Multiple Sclerosis 

9. Multiple Sclerosis Current Treatment and Medical Practices

10. Multiple Sclerosis Unmet Needs

11. Multiple Sclerosis Emerging Therapies

12. Multiple Sclerosis Market Outlook

13. Country-Wise Multiple Sclerosis Market Analysis (2020–2034)

14. Multiple Sclerosis Market Access and Reimbursement of Therapies

15. Multiple Sclerosis Market Drivers

16. Multiple Sclerosis Market Barriers

17.  Multiple Sclerosis Appendix

18. Multiple Sclerosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Recent Posts

T-cell Malignancies Pipeline Report 2024 | Clinical Trials, FDA, EMA, PMDA Approvals, Drugs and Companies

Read Full Article

Categories